This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Systemic lupus erythematosus
DOID EFO MESH SNOMED Endpoint Browser
M13_SLE
systemic lupus erythematosus: An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
M32
Hospital discharge: ICD-9
7100
Hospital discharge: ICD-8
7431
Cause of death: ICD-10
M32
Cause of death: ICD-9
7100
Cause of death: ICD-8
7431
2 out of 7 registries used, show all original rules.
1121
Check minimum number of events None
1121
Include endpoints None
1121
Remove individuals based on genotype QC
1083
M13_SLE
Control definitions
Control exclude
M13_SYSTCONNECT
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
M30-M36
Name in latin
Lupus erythematosus disseminatus (LED)
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Systemic lupus erythematosus
based on the number of shared cases.
Broader endpoints:
- SLE (Finngen)
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Finngen Rheumatological endpoints
- Autoimmune diseases
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1083 | 898 | 185 |
| Unadjusted prevalence (%) | 0.26 | 0.39 | 0.10 |
| Mean age at first event (years) | 45.95 | 44.87 | 51.19 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: M13_SLE – Systemic lupus erythematosus
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Systemic lupus erythematosus
↥Endpoint not on priority list, no data to show.